Clinical AI, drug discovery, devices, and regulatory approvals.
A late-stage study of Bristol Myers Squibb's admilparant was amended to monitor liver injury after a participant died, casting renewed doubt on a drug class already shadowed by toxicity concerns.
A federal judge ruled that a pension fund's lawsuit can proceed on claims UnitedHealth inflated earnings by hiding a scheme to add diagnoses to Medicare Advantage patients' records.
A phase III trial found the once-daily oral GLP-1 receptor agonist orforglipron met cardiovascular safety criteria in high-risk type 2 diabetes patients, though superiority remains unproven.
The FDA is seeking new scientific and consumer voices for advisory committees after a period of fewer meetings under the Trump administration.
In a phase III trial, the all-oral combination nearly doubled progression-free survival versus standard endocrine therapy in patients with ESR1-mutated, ER-positive breast cancer after CDK4/6 inhibitor progression.
A MedCity FemFwd episode explores PwC's findings on growth prospects in fertility and reproductive health.
Two analyses of over 2.5 million procedures found no meaningful difference in 5-year implant survival between robotic and conventional hip and knee replacements, challenging plans to expand robotic surgery in the NHS.
A Trump administration pilot to lower Medicare drug prices will save far less than originally projected after exemptions shrank its scope.
A former White House Covid response coordinator says AI tools and unregulated DNA fragments are making biological attacks more feasible.
Two meta-analyses suggest periconceptional GLP-1 use is not clearly linked to most adverse pregnancy outcomes, but authors stop short of endorsing continued use.
A roundup of recent psychiatry news includes a new VA consent requirement, a promising app for schizophrenia, and a diet-depression trial.
A statewide analysis found maternal sepsis was rare but involved in nearly a third of delivery-associated hospital deaths, with higher risks for Black, Medicaid-covered, and chronically ill mothers.
The agency's priority review could make fenebrutinib the first BTK inhibitor approved for both relapsing and primary progressive multiple sclerosis, though safety questions remain.
New data suggest bispecific antibody regimens may offer a curative path for older, frail patients with diffuse large B-cell lymphoma who cannot tolerate standard chemotherapy.
The agency is exploring whether AI tools could turn the annual wellness visit into a continuous, data-driven preventive care process.
The lawsuit highlights growing friction between U.S. gene-editing firms and Chinese rivals as venture capital flows across borders.
The former House majority leader takes over the drug industry's top lobbying group amid bipartisan pushback on U.S. drug prices.
The Senate will not vote on Heidi Overton's FDA nomination before the November elections, leaving the agency's leadership in limbo.